Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May 21;30(24):3675-82.
doi: 10.1016/j.vaccine.2012.03.031. Epub 2012 Mar 29.

The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients

Yeohan Song  1 , Julie H Y Tai, Sarah M Bartsch, Richard K Zimmerman, Robert R Muder, Bruce Y Lee
Affiliations

The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients

Yeohan Song et al. Vaccine. .

Abstract

Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Markov model structure
FIGURE 2
FIGURE 2
Cost per infection averted for a $100 vaccine with 50% efficacy at varying colonization rates.
See this image and copyright information in PMC

References

    1. Fitzgibbons LN, Puls DL, Mackay K, Forrest GN. Management of gram-positive coccal bacteremia and hemodialysis. Am J Kidney Dis. 2011 Apr;57(4):624–640. - PubMed
    1. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. Infect Dis Clin North Am. 2001 Sep;15(3):731–742. vii. - PubMed
    1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998 Aug 20;339(8):520–532. - PubMed
    1. Alexander EL, Morgan DJ, Kesh S, Weisenberg SA, Zaleskas JM, Kaltsas A, et al. Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York hospital. Diagn Microbiol Infect Dis. 2011 Feb 17;70(1):37–44. - PMC - PubMed
    1. Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol. 2009 Feb;4(2):428–34. - PMC - PubMed

Publication types

Substances